Literature DB >> 12839946

Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma.

Kaiyi Li1, Shiaw-Yih Lin, F Charles Brunicardi, Philip Seu.   

Abstract

RNA interference is the process by which double-stranded RNA directs sequence-specific degradation of mRNA. It has recently been shown that RNA interference can be triggered by 21-nucleotide duplexes of small interfering RNAs (siRNAs) in both cultured mammalian cells and adult mice. We hypothesize that siRNA can be used to specifically target oncogene overexpression in a therapeutic manner. Here, we show that overexpression of the oncogene cyclin E can be suppressed by up to 90% in hepatocellular carcinoma (HCC) cell lines by siRNA targeted on the coding region of cyclin E. We also find that depletion of cyclin E in this manner promotes apoptosis of HCC cells and blocks cell proliferation. Finally, we show that the siRNA oligos inhibits HCC tumor growth in nude mice. Thus, this study demonstrates the therapeutic potential of siRNA on the treatment of HCC by targeting overexpressed oncogenes such as cyclin E. Our results also indicate that cyclin E, which is overexpressed in 70% of HCCs, may serve as a novel therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839946

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma.

Authors:  Chiara Braconi; Nicola Valeri; Takayuki Kogure; Pierluigi Gasparini; Nianyuan Huang; Gerard J Nuovo; Luigi Terracciano; Carlo M Croce; Tushar Patel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.

Authors:  Carlee E Ashley; Eric C Carnes; Genevieve K Phillips; Paul N Durfee; Mekensey D Buley; Christopher A Lino; David P Padilla; Brandy Phillips; Mark B Carter; Cheryl L Willman; C Jeffrey Brinker; Jerri do Carmo Caldeira; Bryce Chackerian; Walker Wharton; David S Peabody
Journal:  ACS Nano       Date:  2011-06-07       Impact factor: 15.881

3.  Cyclin E expression and chemotherapeutic sensitivity in breast cancer cells.

Authors:  Jianying Chen; Guobin Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 4.  Personalized cancer approach: using RNA interference technology.

Authors:  John Nemunaitis; Donald D Rao; Shi-He Liu; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

5.  The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function.

Authors:  Guisheng Zhou; Marie-Claude Gingras; Shi-He Liu; Donghui Li; Zhijun Li; Robbi L Catania; Kelly M Stehling; Min Li; Giovanni Paganelli; Richard A Gibbs; Francesco J Demayo; William E Fisher; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

6.  Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury.

Authors:  Haksier Ehedego; Antje Mohs; Bettina Jansen; Kanishka Hiththetiya; Piotr Sicinski; Christian Liedtke; Christian Trautwein
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

Review 7.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression.

Authors:  Yongxin Zou; Jun Mi; Jinpeng Cui; Defen Lu; Xiyu Zhang; Chenhong Guo; Guimin Gao; Qiji Liu; Bingxi Chen; Changshun Shao; Yaoqin Gong
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

9.  RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.

Authors:  C Yu; X Zhang; G Sun; X Guo; H Li; Y You; J L Jacobs; K Gardner; D Yuan; Z Xu; Q Du; C Dai; Z Qian; K Jiang; Y Zhu; Q Q Li; Y Miao
Journal:  J Cell Mol Med       Date:  2008-02-05       Impact factor: 5.310

10.  MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines.

Authors:  Yukari Takahashi; Alistair R R Forrest; Emi Maeno; Takehiro Hashimoto; Carsten O Daub; Jun Yasuda
Journal:  PLoS One       Date:  2009-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.